Efficacy of romosozumab as sequential therapy for bisphosphonates in glucocorticoid-induced osteoporosis. [PDF]
JBMR PlusKawazoe M +6 more
europepmc +1 more source
Sclerostin as a Putative Myokine in Sarcopenia
Endocrinology and Metabolism, 2022 openaire +3 more sources
<i>Sost</i> deficiency leads to greater bone vascular porosity, but similar osteocyte lacunar properties with increasing age. [PDF]
Bone RepdeVet T +7 more
europepmc +1 more source
Sclerostin And Dkk-1 In Patients With Ankylosing Spondylitis
, 2014 Objective: To determine the serum Dickkopf-related protein 1 (Dkk-1) and sclerostin levels, and their relationship to structural damage and disease activity in patients with ankylosing spondylitis (AS), as well as to compare the serum Dldc-1 and ...
Tok, F. +7 more
core
Biomaterials at the interface of bone-derived factors and inter-organ communication: Current evidence and future perspectives. [PDF]
Bioact MaterJi L, Zhu F, Wang X, Wang J, Liu C.
europepmc +1 more source
Cardiovascular Outcomes Following Therapeutic Sclerostin Inhibition Compared With Alternative Anabolic Therapies: A Real-World Propensity Score-Matched Analysis. [PDF]
J OsteoporosBarnett MJL, Lam J, Anastasopoulou C.
europepmc +1 more source
Increased Serum Levels of Dickkopf-1 and Sclerostin as WNT Signaling Pathway Inhibitors in Celiac Disease Patients. [PDF]
Immun Inflamm DisAl-Ani MNT +5 more
europepmc +1 more source
Editorial: Emerging therapies for metabolic bone diseases. [PDF]
Front Endocrinol (Lausanne)Falchetti A, Gennari L.
europepmc +1 more source
Romosozumab and Cardiovascular Safety: Bridging the Gap between Clinical Trials and Real-World Evidence. [PDF]
Endocrinol Metab (Seoul)Kim BJ.
europepmc +1 more source